Browsing Tag
Bristol Myers Squibb
36 posts
Can Bristol Myers Squibb’s CD19 NEX-T therapy replace lifelong immunosuppression? Early Phase 1 data raises the question
Bristol Myers Squibb’s new CAR T data suggests immune reset potential in lupus, systemic sclerosis, and inflammatory myopathies. Read how the paradigm may shift.
Can psoriatic disease remission be redefined? Inside the shift toward zero activity in targeted domains
Discover how zero disease activity in one or more domains is reshaping psoriatic care, pharma strategy, and future treatment benchmarks.
Bristol Myers Squibb’s CD19 NEX-T therapy shows 94% off immunosuppressants in early Phase 1 results
Bristol Myers Squibb’s CAR T cell therapy shows early promise in autoimmune disorders. Find out what the data means for the stock and the wider market.
The in-vivo revolution: How pharma is racing to reprogram immunity inside the body
Explore how pharma giants like Bristol Myers Squibb are driving the in-vivo revolution to reprogram immunity and transform autoimmune and cancer care.
Can Bristol Myers Squibb’s $1.5bn Orbital deal make in-vivo CAR-T the next big breakthrough in autoimmune care?
Bristol Myers Squibb’s $1.5 B Orbital buyout bets on in-vivo CAR-T and RNA delivery to reshape autoimmune care. Find out what it means for BMY investors.
Analysts weigh Bristol Myers Squibb’s $1.5bn Orbital Therapeutics deal as a bold but risky pivot
Bristol Myers Squibb’s $1.5 billion acquisition of Orbital Therapeutics aims to advance in vivo CAR T for autoimmune diseases and strengthen its RNA platform.
What Sutro Biopharma’s restructuring says about biotech layoffs and investor sentiment in 2025
Sutro Biopharma (NASDAQ: STRO) slashes jobs and narrows its pipeline to extend cash runway into 2027. What does this restructuring mean for investors?
Sotyktu joins Eliquis in Bristol Myers’ direct-to-patient experiment — Is this the future of pharma distribution?
Bristol Myers Squibb adds Sotyktu to its DTC channel with 86% discount, reshaping drug pricing and patient access. See why this matters for pharma.
Why Bristol Myers Squibb is walking away from its first China joint venture after four decades
Bristol Myers Squibb’s 60% stake sale in its China JV shows a pivot from generics to innovation. Find out what this means for its stock and growth outlook.
LOTTE BIOLOGICS secures third major contract of 2025 through new U.S. biopharma manufacturing deal
LOTTE BIOLOGICS wins a third U.S. contract in 2025, boosting its CDMO momentum and investor sentiment. Find out how the deal shapes biomanufacturing strategy.